UNITY Biotechnology, Inc. is a biotechnology company engaged in researching and developing therapeutics to slow, halt or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence, and it is advancing senolytic programs primarily in ophthalmologic disorders. It has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1325 is a potent small molecule inhibitor of BCL-xL. UBX2089, an a-Klotho hormone drug candidate, is being researched for multiple neurology indications.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - OTC Markets Other stock markets 20:00:08 01/10/2025 BST			5-day change	1st Jan Change
0.0561 ^USD	+0.36%		-.--%	-

21/07/25	Unity Biotechnology, Inc. announced that it has received $0.000001 million in funding	CI
11/07/25	Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from S&P TMI Index	CI

Market Cap	966K 834K 769K 719K 1.35M 91.78M 1.37M 9.07M 3.54M 44.67M 3.62M 3.55M 155M	P/E Ratio 2023	-0.72x	P/E Ratio 2024	-0.63x
Enterprise Value	1.27M 1.1M 1.01M 950K 1.78M 121M 1.81M 11.98M 4.67M 58.97M 4.78M 4.68M 204M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	98.1%	Yield 2023 *	-	Yield 2024	-

21/07/25	Unity Biotechnology, Inc. announced that it has received $0.000001 million in funding	CI
11/07/25	Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from S&P TMI Index	CI
09/07/25	Unity Biotechnology, Inc. will Change its Ticker to UNBX from UBX	CI
07/07/25	Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from NASDAQ Composite Index	CI
27/05/25	HC Wainwright Downgrades Unity Biotechnology to Neutral From Buy, Adjusts Price Target to $2 From $4	MT
16/05/25	Mizuho Downgrades Unity Biotechnology to Neutral From Outperform After Diabetic Edema Treatment Misses Primary Endpoint, Cuts Price Target to $1 From $6	MT
05/05/25	UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force	RE
05/05/25	UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates	CI
23/04/25	UNITY Biotechnology, Inc. Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME	CI
22/04/25	Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
04/04/25	Unity Biotechnology, Inc. Announces Resignation of Paul L. Berns as a Member of the Board and All of the Committees of the Board	CI
25/03/25	Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating	MT
24/03/25	Equity Markets Close Higher on Private Sector Growth Data	MT

27/05/25	HC Wainwright Downgrades Unity Biotechnology to Neutral From Buy, Adjusts Price Target to $2 From $4	MT
16/05/25	Mizuho Downgrades Unity Biotechnology to Neutral From Outperform After Diabetic Edema Treatment Misses Primary Endpoint, Cuts Price Target to $1 From $6	MT
25/03/25	Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating	MT
24/03/25	HC Wainwright Adjusts Unity Biotechnology Price Target to $4 From $8, Maintains Buy Rating	MT
16/04/24	HC Wainwright Adjusts Unity Biotechnology Price Target to $8 From $10, Maintains Buy Rating	MT

Unity Biotechnology, Inc. Share Price

Stocks

UBX

US91381U2006

Biotechnology & Medical Research

Valuation: Unity Biotechnology, Inc.

Chart: Unity Biotechnology, Inc.

Latest news : Unity Biotechnology, Inc.

Analysts' recommendations: Unity Biotechnology, Inc.

Press Releases: Unity Biotechnology, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Unity Biotechnology, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

05/05/25	UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates	AQ
01/05/25	UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting	AQ
23/04/25	UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME	AQ
22/04/25	UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates	AQ
24/03/25	UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema	AQ

1 year	0.05	0.85
3 years	0.05	3.48
5 years	0.05	49.7
10 years	0.05	245.6

Manager	Title	Age	Since
Craig Jalbert CEO	Chief Executive Officer	64	26/06/2025
Federico Grossi CTO	Chief Tech/Sci/R&D Officer	51	05/01/2025
Przemyslaw Sapieha CTO	Chief Tech/Sci/R&D Officer	-	31/01/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/04/25	Lynne Sullivan	Sell	Chief Financial Officer	21,867	0.1298%
01/04/25	Alexander Nguyen	Sell	Consultant / conseiller	17,852	0.1059%
01/04/25	Anirvan Ghosh	Sell	Chief Executive Officer	96,797	0.5745%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
UNITY BIOTECHNOLOGY, INC.	+0.36%	-.--%	-92.97%	-98.35%	966K
ARGENX SE	+1.03%	+2.30%	+55.91%	+114.22%	56.42B
WUXI APPTEC CO., LTD.	+2.72%	+3.26%	+46.05%	+44.91%	44.54B
BIONTECH SE	+1.12%	+2.79%	-15.04%	-21.68%	22.9B
INSMED INCORPORATED	+1.17%	+3.85%	-0.89%	+403.86%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-5.07%	+11.00%	-30.62%	16.4B
GENMAB A/S	+0.15%	+2.24%	+9.32%	-39.30%	15.4B
EXELIXIS, INC.	-0.69%	+0.82%	+27.75%	+176.72%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+5.54%	+19.65%	-	12.36B
PHARMAESSENTIA CORPORATION	+1.61%	+1.28%	+95.75%	+205.26%	11.15B
Average	+1.66%	+1.23%	+15.65%	+83.89%	21.37B
Weighted average by Cap.	+1.72%	+2.37%	+32.04%	+99.59%

	2023	2024
Net sales	-	-
Net income	-39.86M -34.43M -31.72M -29.7M -55.65M -3.79B -56.51M -375M -146M -1.84B -150M -146M -6.39B	-25.99M -22.45M -20.69M -19.36M -36.29M -2.47B -36.85M -244M -95.23M -1.2B -97.54M -95.46M -4.16B
Net Debt	-16.21M -14M -12.9M -12.08M -22.63M -1.54B -22.98M -152M -59.4M -750M -60.84M -59.54M -2.6B	309K 267K 246K 230K 431K 29.37M 438K 2.9M 1.13M 14.3M 1.16M 1.13M 49.5M